Conjugate vaccines combine polysaccharides from bacteria or capsule polymers with a immunogenic carrier protein to generate a stronger adaptive immune response. Conjugating polysaccharides to protein carriers modulates and enhances the immune response elicited against polysaccharide antigens.
The global conjugate vaccine market is estimated to be valued at US$ 22741.91 Bn in 2024 and is expected to exhibit a CAGR of 26% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the conjugate vaccine market are RSA Security (DELL EMC), Carbon Black Inc., McAfee Corporation, Cisco Systems Inc., OpenText Corporation, FireEye Inc., CrowdStrike Inc., Digital Guardian, Broadcom Inc., Deep Instinct, and Cybereason Inc. Key players are focusing on introducing new conjugate vaccines with greater efficacy and expanding their product portfolio. Rising demand for combination vaccines to prevent multiple diseases simultaneously is expected to drive market growth over the forecast period. Technological advancements including integration with artificial intelligence and machine learning for developing new conjugate vaccines is also expected to support the market expansion.
Market Trends
Growing popularity of combination vaccines: Combination vaccines help prevent multiple diseases with fewer injections. For example, vaccines that protect against diphtheria, tetanus, pertussis, polio, and Hib are available as combination vaccines. Increasing popularity of such combination vaccines is expected to boost the conjugate vaccine market.
Rising focus on meningitis vaccination: Increasing incidence of meningococcal meningitis worldwide has boosted the demand for meningococcal conjugate vaccines. The introduction of new quadrivalent meningococcal conjugate vaccines which protects against four serogroups is expected to support the market growth over the forecast period.
Market Opportunities
Development of thermostability: Development of thermostable conjugate vaccines which do not require cold chain for transportation and storage will help in effective vaccination programs especially in tropical countries and remote locations. This is expected to create significant opportunities for conjugate vaccine manufacturers.
Focus on universal flu vaccine: Significant efforts are underway to develop a universal flu vaccine which will induce long-lasting immunity against various flu strains. Development of an effective universal flu vaccine incorporating conjugate vaccine technology presents lucrative growth prospects.
Impact of COVID-19 on Global Conjugate Vaccine Market Size Growth
The COVID-19 pandemic has significantly impacted the growth of the conjugate vaccine market globally. The shutdowns and supply chain disruptions caused delays in routine immunization programs worldwide. The pandemic diverted healthcare resources from routine services towards COVID care, resulting in lower vaccination coverage rates. This posed risks of outbreaks of vaccine-preventable diseases.
However, with increasing vaccination drives post lockdowns, the market is recovering. Various countries are now focusing on catch-up immunization campaigns to boost routine vaccination rates. Manufacturers are ramping up production capacities to meet the growing demand. Researchers are also exploring the development of conjugate vaccines for COVID-19. If successful, these vaccines can help boost the market in the coming years.
Going forward, as vaccination programs stabilize, the market is expected to grow steadily. Increased focus on pandemic preparedness may also drive long-term demand. Continuous research for new conjugate vaccines against various diseases will further support market expansion. Collaborations between health authorities and manufacturers are vital for ensuring consistent supply and accessibility of these life-saving vaccines worldwide.
Conjugate Vaccine Market in North America
North America accounts for the largest share of the global conjugate vaccine market in terms of value. This is majorly attributed to the strong healthcare infrastructure and high patient awareness in the region. The United States dominates the North American market and is one of the leading countries to introduce new conjugate vaccines regularly. Due to the COVID-19 outbreak, the region witnessed initial disruptions but is recovering steadily now with expanding vaccination programs across nations. The market in North America is anticipated to continue dominating in the coming years with robust government support and advanced research capabilities.
Conjugate Vaccine Market in Asia Pacific
The Asia Pacific region is recognized as the fastest growing regional market for conjugate vaccines globally. This growth can be credited to factors like the rising prevalence of infectious diseases, growing healthcare spending, increasing focus on immunization by UNICEF, WHO, and other non-profits in developing Asia Pacific countries. Countries like India and China are the major revenue contributors due to their huge population base and expanding vaccine production facilities. The COVID-19 pandemic had a short-term impact, but governments are now prioritizing routine immunization again to achieve coverage targets. Thus, the Asia Pacific conjugate vaccine market is projected for substantial growth in the forecast period.
Get More Insights On This Topic: Conjugate Vaccine Market
Global Conjugate Vaccines Market Research Report, By Type (Haemophilus B, Monovalent, Multivalent, And Others), By Indication (Influenza, Pneumococcal, Meningococcal, And Others) By End Users (Pediatrics And Adults) - Global Forecast Till 2027SegmentationThe global conjugate vaccine is segmented on the basis of type, indication, and end users.
On the basis of end users, it is segmented into pediatrics and adults.Get Sample Report at https://www.marketresearchfuture.com/sample_request/4387Market HighlightsConjugates vaccines are formed by covalently bonding a weak antigen to the strong antigen, it boosts the hosts’ immune response.
Vaccines are given to children to prevent transmission of diseases through infections and seasonal variation.
Young children are more susceptible to infection that drives growth of the market.
Moreover, increasing government support is expected to fuel the market’s growth during the forecast period.
The effectiveness of vaccine conjugates and need more advanced research, which may hinder the growth of the market during the forecasted period.The Global Conjugate Vaccine Market is expected to grow at a CAGR of 10.5% during the forecast period 2017-2027.Taste the market data and market information presented through more than 105 market data tables and figures spread over 115 pages of the project report.
Vaccine Conjugate Market Growing Demand for Disease Eradication in Global OpportunitiesThe report studies the global Vaccine Conjugate Market’s historical growth trajectory in order to provide pointers as to the major drivers and restraints affecting the market’s growth prospects and derive market growth markers that can indicate the market’s future growth trajectory over the forecast period from 2017 to 2023.The global Vaccine Conjugate Market is expected to exhibit a robust 10.5% CAGR over the forecast period, according to MRFR.Conjugate vaccines are vaccines containing two antigens, one strong and one weak.
The stronger antigen is generally made from proteins and is attached to a weaker polysaccharide antigen to form conjugate vaccines.Competitive Analysis:Leading players in the global Vaccine Conjugate Market include,GSK plcFablifeSanofi Pasteur SASinovac Biotech Ltd.GreenSignal Bio Pharma LimitedBavarian NordicTaj Pharmaceuticals LimitedIDT BiologicsPfizerSutroVax Inc.and Merck & Co. Inc.Avail Free Sample@ https://www.marketresearchfuture.com/sample_request/4387Conjugate vaccines are used to counter diseases whose associated pathogens do not elicit a significant response from the human immune system on their own.
As a result, a stronger antigen is attached to the weaker pathogen to make it more prominent and to elicit a stronger response from the immune system.
The first conjugate vaccine was developed in response to the outbreak of meningitis, which still remains among the top targeted diseases in the Vaccine Conjugate Market.The growing government support for mass-scale vaccinations for disease eradication is likely to remain the prime driver for the global Vaccine Conjugate Market over the forecast period.
Vaccination has taken on a key role in eliminating diseases such as meningitis, which can become a serious health problem given the right conditions.
The growing support for further advancement in vaccine research and development is also likely to be a major driver for the global Vaccine Conjugate Market over the forecast period.
